AUTHORS
Izel Okcu, MD, Zhuo Li2, Launia White3, Yucai Wang, MD, PhD4, Patrick Johnston, MD, PhD5, Allison C Rosenthal, DO6, Arushi Khurana, MBBS7, Urshila Durani, MD, MPH8, Jonas Paludo, MD9, Madiha Iqbal, MBBS, MD10, Muhamad Alhaj Moustafa, MD, MS11, Rebecca L. King, MD12, Thomas Witzig, MD13, Thomas M. Habermann, MD14, Grzegorz Nowakowski, MD15, Han W Tun, MD16
AFFILIATIONS
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Jacksonville, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Phoenix, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Jacksonville, United States
11 Mayo Clinic, Jacksonville, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Jacksonville, United States
ABSTRACT
Background:
Secondary central nervous system lymphoma (SCNSL) refers to central nervous system (CNS) involvement at the time of initial diagnosis (de novo SCNSL, DN-SCNSL) or at relapse (relapsed SCNSL, R-SCNSL). High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements (double-hit/triple-hit lymphoma; DHL/THL) carries a marked tropism for the CNS. Despite this recognized risk, the clinical patterns, molecular correlates, and prognostic drivers of SCNSL within this molecular subset remain poorly defined, and outcomes are largely uncharacterized. We report the clinical, molecular, and survival characteristics of de novo and relapsed secondary CNS DHL/THL (DN-SCNS-DHL/THL and R-SCNS-DHL/THL) in a single-institution HGBCL-DHL/THL cohort.
Methods:
Patients with SCNS-DHL/THL treated at Mayo Clinic between 2002 and 2025 were identified. MYC, BCL2, and/or BCL6 rearrangements were assessed by fluorescence in situ hybridization (FISH) on primary systemic lymphoma tissue. Clinical, pathologic, and treatment data were abstracted from medical records. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method, and univariable prognostic associations were tested by log-rank test.
Results:
A total of 57 patients were included; 43 (75%) had R-SCNS-DHL/THL and 14 (25%) had DN-SCNS-DHL/THL. BCL2 and BCL6 rearrangements by FISH were identified in 43/57 (75.4%) and 32/54 (59.3%) patients, respectively. In both cohorts, CNS involvement was predominantly leptomeningeal, parenchymal disease was usually multifocal, and BCL6 positivity by immunohistochemistry was frequent (DN, 8/11 [72.7%]; R, 28/38 [73.7%]).
In the de novo cohort (n=14), the median age was 68 years, and 50.0% were female. At diagnosis, bone marrow (BM) involvement was present in 7/14 (50.0%). CNS disease was leptomeningeal in 11/14 (78.6%) and parenchymal in 3/14 (21.4%); all parenchymal lesions were multifocal. One patient (7.1%) had both leptomeningeal and parenchymal involvement. Induction was most commonly MR-CHOP (6/14, 42.9%), DA-EPOCH-R (5/14, 35.7%), or R-CODOX-M/IVAC (3/14, 21.4%), yielding complete response (CR) in 9/14 (64.3%) and partial response (PR) in 1/14 (7.1%). Autologous stem cell transplantation (ASCT) was performed in 3/14 (21.4%). Estimated 1-year OS and PFS were 45.8% (95% CI, 25.0%–84.0%) and 39.0% (95% CI, 19.0%–79.0%), respectively.
In the relapsed cohort (n=43), the median age was 65 years, and 48.8% were female. At initial diagnosis, BM involvement was present in 9/41 (22.0%). At CNS relapse, disease was CNS-only in 35/43 (81.4%) and systemic in 8/43 (18.6%); CNS distribution was leptomeningeal in 24/43 (55.8%) and parenchymal in 14/43 (32.6%; multifocal in 57.1%) of cases, and combined in 5/43 (11.6%). Frontline induction was R-CHOP (26/43, 60.5%), DA-EPOCH-R (11/43, 25.6%), R-CODOX-M/IVAC (1/43, 2.3%), or other regimens (5/43, 11.6%), resulting in CR in 26/43 (60.5%) and PR in 1/43 (2.3%). CNS prophylaxis was given to 14/43 (32.6%), including intrathecal chemotherapy (8/41, 19.5%) and intravenous high-dose methotrexate (HD-MTX; 4/41, 9.8%). Consolidation ASCT was performed in 5/43 (11.6%). Relapses occurred early, with a median time to relapse of 6.8 months and 79.1% occurring within 1 year. Salvage regimens included rituximab plus HD-MTX (9/43, 20.9%), MATRix (2/43, 4.7%), MRT (10/43, 23.3%), and others (18/43, 41.9%); overall response rate to salvage therapy was 27.6% (8/29, all CR). Estimated 1-year OS and PFS were 33.1% (95% CI, 20.5%–53.5%) and 10.8% (95% CI, 4.3%–27.1%), respectively.
In the R-SCNS-DHL/THL cohort, BCL6 positivity by IHC (p=0.007) and absence of BM involvement (p=0.006) at initial diagnosis were each associated with improved OS. Post-salvage ASCT (6/43, 14.0%) was associated with superior 1-year OS (66.7% vs 26.6%; p=0.035).
Conclusions:
In this SCNS-DHL/THL cohort, secondary CNS involvement arose most often at relapse and was marked by frequent early relapse and predominantly leptomeningeal disease. Among R-SCNS-DHL/THL patients, BCL6 positivity and the absence of BM involvement at initial diagnosis were associated with favorable OS, and post-salvage ASCT was associated with a survival benefit. Outcomes of SCNS-DHL/THL were poor, particularly in R-SCNS-DHL/THL, suggesting that more effective CNS-directed and systemic therapies are needed in DHL/THL.
DISCLOSURES
Izel Okcu, MD: No relevant conflicts of interest to declare.